EMEA-002206-PIP02-19

Table of contents

Key facts

Active substance
Rebisufligene etisparvovec
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0366/2020
PIP number
EMEA-002206-PIP02-19
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)
Route(s) of administration
Intravenous use
Contact for public enquiries
Abeona Therapeutics Inc.
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating